Conditions: Allergy
Keywords: Immunology
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 914
Healthy volunteers: no

Brief summary:
This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary objective was to compare treatment-emergent adverse events (AEs) for participants treated with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.

Detailed description:

Arms:
arm 1: 12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily. arm 2: Matching placebo tablet, sublingual, once daily.

Interventions: intervention 1: SCH 39641 intervention 2: Placebo for SCH 39641
Intervention descriptions: intervention 1: Rapidly dissolving tablet sublingually once daily intervention 2: Rapidly dissolving tablet sublingually once daily

Protocol document: